David Hsieh
University of Texas Southwestern Medical Center · Assistant Professor · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Hsieh as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:04 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07878689 · Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaUniversity of Texas Southwestern Medical Center · not yet recruiting · Hepatocellular Carcinoma (HCC) · principal investigator
- Ph2NCT07689175 · Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaUniversity of Texas Southwestern Medical Center · recruiting · Hepatocellular Carcinoma (HCC) · principal investigator
- Ph2NCT06789848 · Ligufalimab and Cadonilimab in Advanced Liver CancersUniversity of Texas Southwestern Medical Center · recruiting · Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer · principal investigator
- Ph2NCT05724563 · Domvanalimab and Zimberelimab in Advanced Liver CancersUniversity of Texas Southwestern Medical Center · active not recruiting · Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma · principal investigator
- Ph2NCT05537402 · LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCCUniversity of Texas Southwestern Medical Center · terminated · Hepatocellular Carcinoma · principal investigator
- Ph2NCT05249569 · Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaUniversity of Texas Southwestern Medical Center · terminated · Hepatocellular Carcinoma · principal investigator
- Ph2NCT05211323 · A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerNational Cancer Institute (NCI) · active not recruiting · Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer · principal investigator
- Ph2NCT03519997 · A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular CarcinomaDavid Hsieh · completed · Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Defining mechanisms of immunotherapy resistance and targeting TIGIT in hepatobiliary cancersK08CA290062 · NCI · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2025 to 2026 · $270,981 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT05211323
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:04 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan.Clin Lung Cancer · 2012111 citationsRCR 3.3
- Extended bandwidth nonlinear frequency compression in Mandarin-speaking hearing-aid users.J Formos Med Assoc · 20185 citationsRCR 0.5